The Janssen results aren't far off either; Q3 of this FY so we have news scheduled for some time in Jan to Mar 2020. If things go well our revenue pipeline will be fasttracked and no doubt the SP will rerate. In the mean time there are a number of positive developments that can pop up at any time like a US distribution partner, and the ramping of revenue from the current licensees. Guardia is a wildcard, I think there's more there than they are telling us. Why suspend endometriosis and not guardia? Would have thought Endometriosis to be the more important from a market perspective so I'm thinking that validation for Guardia is all but a foregone conclusion... or am I just contra-conspiracy nutjob?
The Janssen results aren't far off either; Q3 of this FY so we...
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
-0.030(4.32%) |
Mkt cap ! $87.11M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 68.5¢ | 65.5¢ | $74.33K | 111.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10373 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.0¢ | 21598 | 5 |
View Market Depth
| Last trade - 13.25pm 04/10/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |